Author:
Gimenes-Teixeira Hamilton L,Lucena-Araujo Antonio R,dos Santos Guilherme A,Zanette Dalila L,Scheucher Priscila S,Oliveira Luciana C,Dalmazzo Leandro F,Silva-Júnior Wilson A,Falcão Roberto P,Rego Eduardo M
Abstract
Abstract
Background
CD56 expression has been associated with a poor prognosis in lymphoid neoplasms, including T-cell acute lymphoblastic leukemia (T-ALL). MicroRNAs (miRNAs) play an important role in lymphoid differentiation, and aberrant miRNA expression has been associated with treatment outcome in lymphoid malignancies. Here, we evaluated miRNA expression profiles in normal thymocytes, mature T-cells, and T-ALL samples with and without CD56 expression and correlated microRNA expression with treatment outcome.
Methods
The gene expression profile of 164 miRNAs were compared for T-ALL/CD56+ (n=12) and T-ALL/CD56- (n=36) patients by Real-Time Quantitative PCR. Based on this analysis, we decided to evaluate miR-221 and miR-374 expression in individual leukemic and normal samples.
Results
miR-221 and miR-374 were expressed at significantly higher levels in T-ALL/CD56+ than in T-ALL/CD56- cells and in leukemic blasts compared with normal thymocytes and peripheral blood (PB) T-cells. Age at diagnosis (15 or less vs grater than 15 years; HR: 2.19, 95% CI: 0.98-4.85; P=0.05), miR-221 expression level (median value as cut off in leukemic samples; HR: 3.17, 95% CI: 1.45-6.92; P=0.004), and the expression of CD56 (CD56-
vs CD56+; HR: 2.99, 95% CI: 1.37-6.51; P=0.006) were predictive factors for shorter overall survival; whereas, only CD56 expression (HR: 2.73, 95% CI: 1.03-7.18; P=0.041) was associated with a shorter disease-free survival rate.
Conclusions
miR-221 is highly expressed in T-ALL and its expression level may be associated with a poorer prognosis.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Hematology
Reference33 articles.
1. Farag SS, VanDeusen JB, Fehniger TA, Caligiuri MA: Biology and clinical impact of human natural killer cells. Int J Hematol 2003, 78: 7–17. 10.1007/BF02983234
2. Kwong YL, Anderson BO, Advani R, Kim WS, Levine AM, Lim ST: Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009, 10: 1093–1101. 10.1016/S1470-2045(09)70265-7
3. Harabuchi Y, Takahara M, Kishibe K, Moriai S, Nagato T, Ishii H: Nasal natural killer (NK)/T-cell lymphoma: clinical, histological, virological, and genetic features. Int J Clin Oncol 2009, 14: 181–190. 10.1007/s10147-009-0882-7
4. Dalmazzo LF, Jacomo RH, Marinato AF, Figueiredo-Pontes LL, Cunha RL, Garcia AB, et al.: The presence of CD56/CD16 in T-cell acute lymphoblastic leukaemia correlates with the expression of cytotoxic molecules and is associated with worse response to treatment. Br J Haematol 2009, 144: 223–229. 10.1111/j.1365-2141.2008.07457.x
5. Montero I, Rios E, Parody R, Perez-Hurtado JM, Martin-Noya A, Rodriguez JM: CD56 in T-cell acute lymphoblastic leukaemia: a malignant transformation of an early myeloid-lymphoid progenitor? Haematologica 2003, 88: ELT26.
Cited by
48 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献